ABL Bio finished weak in after-hours trading on the 2nd. As the government moves to fully launch 'K-Moonshot,' a drug development system combining artificial intelligence (AI) and automated experiments, attention in the biotech sector is also focusing on changes in the research and development ecosystem.

◆ ABL Bio Stock Price Trend

ABL Bio closed at 51,800 won in after-hours trading that day, down 1,800 won, or 3.36%, from the reference price of 53,600 won. The opening price was 53,900 won, and the stock rose to as high as 54,800 won intraday before falling back to 50,000 won. Trading volume was 480,033 shares, with transaction value at about 25 billion won.

◆ What Is the AI Drug Development 'K-Moonshot'

The government is pursuing the establishment of a 'circular' drug development research system in which AI is used to find drug candidate substances, they are verified in an automated experimental environment, and the experimental results are then learned again by AI. The Ministry of Science and ICT is promoting this AI-based drug development model as 'K-Moonshot.' The key is connecting drug candidate discovery → experimentation → data accumulation → subsequent learning into a single research process.

Conventional drug development involves repeated experimentation and validation after candidate discovery, requiring considerable time and cost. The government's plan is to combine AI and automation technologies with this process to enhance the research system in a way that speeds up research and reduces the likelihood of failure.

◆ First Innovation Research Hub Launched in Daegu

The first innovation research hub will be established in Daegu. On the 12th of last month, the Ministry of Science and ICT held an event in Daegu to launch the demonstration project team for an AI-bio convergence research hub in the synthetic drug field and unveiled the direction of related projects.

At the Daegu hub, an automated experimental system will verify drug candidate substances proposed by AI, and the AI will then learn from the results to improve the accuracy of the next candidate search. Through this, the government plans to build a research environment in which data accumulated during drug development is used repeatedly and AI models and experimental systems complement each other.

◆ Industry Ripple Effects and Investment Cautions

The biotech industry is also watching the possibility that this policy could expand research cooperation beyond AI drug development platform companies to antibody and drug candidate developers, research equipment makers, and bio data companies.

ABL Bio is a biotech company developing bispecific antibody-based drug candidates, with cancer and degenerative brain diseases as its main research areas.

However, it is difficult to conclude that the government's expansion of AI drug development policy will directly affect ABL Bio's performance or corporate value. Participation in government research projects, each company's technology development stage, clinical trial results, and technology transfer achievements need to be confirmed separately. In particular, since biotech stocks are heavily influenced by individual variables such as clinical results, technology transfer contracts, R&D costs, and fundraising plans, caution is needed in interpreting stock price movements based on policy themes alone.

As the government fully pursues a drug development system combining AI and automated research environments, attention is focused on whether changes in R&D methods will continue in the domestic biotech industry.

[This article does not recommend buying or selling specific stocks, and investment decisions and responsibilities rest with the investor. Details of government policies and research projects may change during the implementation process. AI assistance was used in writing and restructuring this article.]